Structure-guided development of covalent TAK1 inhibitors

Li Tan, Deepak Gurbani, Ellen L. Weisberg, John C. Hunter, Lianbo Li, Douglas S. Jones, Scott B. Ficarro, Samar Mowafy, Chun Pong Tam, Suman Rao, Guangyan Du, James D. Griffin, Peter K. Sorger, Jarrod A. Marto, Kenneth D. Westover, Nathanael S. Gray

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

TAK1 (transforming growth factor-β-activated kinase 1) is an essential intracellular mediator of cytokine and growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of a series of 2,4-disubstituted pyrimidine covalent TAK1 inhibitors that target Cys174, a residue immediately adjacent to the ‘DFG-motif’ of the kinase activation loop. Co-crystal structures of TAK1 with candidate compounds enabled iterative rounds of structure-based design and biological testing to arrive at optimized compounds. Lead compounds such as 2 and 10 showed greater than 10-fold biochemical selectivity for TAK1 over the closely related kinases MEK1 and ERK1 which possess an equivalently positioned cysteine residue. These compounds are smaller, more easily synthesized, and exhibit a different spectrum of kinase selectivity relative to previously reported macrocyclic natural product TAK1 inhibitors such as 5Z-7-oxozeanol.

Original languageEnglish (US)
Pages (from-to)838-846
Number of pages9
JournalBioorganic and Medicinal Chemistry
Volume25
Issue number3
DOIs
StatePublished - Feb 1 2017

Fingerprint

Phosphotransferases
Mitogen-Activated Protein Kinase 3
Immune System Diseases
Transforming Growth Factors
Lead compounds
Biological Products
Cysteine
Intercellular Signaling Peptides and Proteins
Cytokines
Crystal structure
Chemical activation
Neoplasms
Testing
Therapeutics
Lead
pyrimidine
7-oxozeanol

Keywords

  • 2,4-Disubstituted pyrimidine
  • Covalent inhibitors
  • Structure-activity relationship
  • Structure-based design
  • TAK1 kinase inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Tan, L., Gurbani, D., Weisberg, E. L., Hunter, J. C., Li, L., Jones, D. S., ... Gray, N. S. (2017). Structure-guided development of covalent TAK1 inhibitors. Bioorganic and Medicinal Chemistry, 25(3), 838-846. https://doi.org/10.1016/j.bmc.2016.11.035

Structure-guided development of covalent TAK1 inhibitors. / Tan, Li; Gurbani, Deepak; Weisberg, Ellen L.; Hunter, John C.; Li, Lianbo; Jones, Douglas S.; Ficarro, Scott B.; Mowafy, Samar; Tam, Chun Pong; Rao, Suman; Du, Guangyan; Griffin, James D.; Sorger, Peter K.; Marto, Jarrod A.; Westover, Kenneth D.; Gray, Nathanael S.

In: Bioorganic and Medicinal Chemistry, Vol. 25, No. 3, 01.02.2017, p. 838-846.

Research output: Contribution to journalArticle

Tan, L, Gurbani, D, Weisberg, EL, Hunter, JC, Li, L, Jones, DS, Ficarro, SB, Mowafy, S, Tam, CP, Rao, S, Du, G, Griffin, JD, Sorger, PK, Marto, JA, Westover, KD & Gray, NS 2017, 'Structure-guided development of covalent TAK1 inhibitors', Bioorganic and Medicinal Chemistry, vol. 25, no. 3, pp. 838-846. https://doi.org/10.1016/j.bmc.2016.11.035
Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS et al. Structure-guided development of covalent TAK1 inhibitors. Bioorganic and Medicinal Chemistry. 2017 Feb 1;25(3):838-846. https://doi.org/10.1016/j.bmc.2016.11.035
Tan, Li ; Gurbani, Deepak ; Weisberg, Ellen L. ; Hunter, John C. ; Li, Lianbo ; Jones, Douglas S. ; Ficarro, Scott B. ; Mowafy, Samar ; Tam, Chun Pong ; Rao, Suman ; Du, Guangyan ; Griffin, James D. ; Sorger, Peter K. ; Marto, Jarrod A. ; Westover, Kenneth D. ; Gray, Nathanael S. / Structure-guided development of covalent TAK1 inhibitors. In: Bioorganic and Medicinal Chemistry. 2017 ; Vol. 25, No. 3. pp. 838-846.
@article{408a43e08719412fa8adce5904e4d10f,
title = "Structure-guided development of covalent TAK1 inhibitors",
abstract = "TAK1 (transforming growth factor-β-activated kinase 1) is an essential intracellular mediator of cytokine and growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of a series of 2,4-disubstituted pyrimidine covalent TAK1 inhibitors that target Cys174, a residue immediately adjacent to the ‘DFG-motif’ of the kinase activation loop. Co-crystal structures of TAK1 with candidate compounds enabled iterative rounds of structure-based design and biological testing to arrive at optimized compounds. Lead compounds such as 2 and 10 showed greater than 10-fold biochemical selectivity for TAK1 over the closely related kinases MEK1 and ERK1 which possess an equivalently positioned cysteine residue. These compounds are smaller, more easily synthesized, and exhibit a different spectrum of kinase selectivity relative to previously reported macrocyclic natural product TAK1 inhibitors such as 5Z-7-oxozeanol.",
keywords = "2,4-Disubstituted pyrimidine, Covalent inhibitors, Structure-activity relationship, Structure-based design, TAK1 kinase inhibitors",
author = "Li Tan and Deepak Gurbani and Weisberg, {Ellen L.} and Hunter, {John C.} and Lianbo Li and Jones, {Douglas S.} and Ficarro, {Scott B.} and Samar Mowafy and Tam, {Chun Pong} and Suman Rao and Guangyan Du and Griffin, {James D.} and Sorger, {Peter K.} and Marto, {Jarrod A.} and Westover, {Kenneth D.} and Gray, {Nathanael S.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.bmc.2016.11.035",
language = "English (US)",
volume = "25",
pages = "838--846",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Structure-guided development of covalent TAK1 inhibitors

AU - Tan, Li

AU - Gurbani, Deepak

AU - Weisberg, Ellen L.

AU - Hunter, John C.

AU - Li, Lianbo

AU - Jones, Douglas S.

AU - Ficarro, Scott B.

AU - Mowafy, Samar

AU - Tam, Chun Pong

AU - Rao, Suman

AU - Du, Guangyan

AU - Griffin, James D.

AU - Sorger, Peter K.

AU - Marto, Jarrod A.

AU - Westover, Kenneth D.

AU - Gray, Nathanael S.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - TAK1 (transforming growth factor-β-activated kinase 1) is an essential intracellular mediator of cytokine and growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of a series of 2,4-disubstituted pyrimidine covalent TAK1 inhibitors that target Cys174, a residue immediately adjacent to the ‘DFG-motif’ of the kinase activation loop. Co-crystal structures of TAK1 with candidate compounds enabled iterative rounds of structure-based design and biological testing to arrive at optimized compounds. Lead compounds such as 2 and 10 showed greater than 10-fold biochemical selectivity for TAK1 over the closely related kinases MEK1 and ERK1 which possess an equivalently positioned cysteine residue. These compounds are smaller, more easily synthesized, and exhibit a different spectrum of kinase selectivity relative to previously reported macrocyclic natural product TAK1 inhibitors such as 5Z-7-oxozeanol.

AB - TAK1 (transforming growth factor-β-activated kinase 1) is an essential intracellular mediator of cytokine and growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of a series of 2,4-disubstituted pyrimidine covalent TAK1 inhibitors that target Cys174, a residue immediately adjacent to the ‘DFG-motif’ of the kinase activation loop. Co-crystal structures of TAK1 with candidate compounds enabled iterative rounds of structure-based design and biological testing to arrive at optimized compounds. Lead compounds such as 2 and 10 showed greater than 10-fold biochemical selectivity for TAK1 over the closely related kinases MEK1 and ERK1 which possess an equivalently positioned cysteine residue. These compounds are smaller, more easily synthesized, and exhibit a different spectrum of kinase selectivity relative to previously reported macrocyclic natural product TAK1 inhibitors such as 5Z-7-oxozeanol.

KW - 2,4-Disubstituted pyrimidine

KW - Covalent inhibitors

KW - Structure-activity relationship

KW - Structure-based design

KW - TAK1 kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85008214319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008214319&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2016.11.035

DO - 10.1016/j.bmc.2016.11.035

M3 - Article

VL - 25

SP - 838

EP - 846

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 3

ER -